Scarica l'app Stockscreener
8.16
5.97%
0.46
Precedente Chiudi:
$7.70
Aprire:
$7.73
Volume 24 ore:
58,306
Relative Volume:
0.30
Capitalizzazione di mercato:
$162.03M
Reddito:
$66.59M
Utile/perdita netta:
$-104.93M
Rapporto P/E:
-1.6485
EPS:
-4.95
Flusso di cassa netto:
$-96.48M
1 W Prestazione:
+9.53%
1M Prestazione:
+29.73%
6M Prestazione:
+45.97%
1 anno Prestazione:
-39.33%
Intervallo 1D:
$7.705
$8.17
Intervallo di 1 settimana:
$7.2327
$8.16
Portata 52W:
$4.09
$17.23
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Nome
Enanta Pharmaceuticals Inc
Settore
Industria
Telefono
617 607 0800
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Confronta ENTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
8.17 | 162.03M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.47 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.51 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.36 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.48 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-09 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-09 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-01-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Iniziato | Evercore ISI | Underperform |
| 2020-08-28 | Ripresa | ROTH Capital | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-27 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Iniziato | Wolfe Research | Outperform |
| 2019-04-23 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-12-13 | Iniziato | Berenberg | Hold |
| 2018-06-06 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-07-11 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | Barclays | Underweight |
| 2015-10-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
Mostra tutto
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com
ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World
Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus
Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals discovers new 17β-HSD13 inhibitors - BioWorld MedTech
Enanta Pharmaceuticals’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com Nigeria
Enanta to present RSV drug study results at ESPID 2025 By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - BioSpace
Enanta to present RSV drug study results at ESPID 2025 - Investing.com
(ENTA) On The My Stocks Page - news.stocktradersdaily.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Citizens JMP Increases Enanta (ENTA) Price Target to $23 | ENTA Stock News - GuruFocus
ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView
Enanta stock price target raised to $23 by JMP - Investing.com Canada
Enanta price target raised to $23 from $21 at Citizens JMP - TipRanks
Enanta (ENTA) Reports Revenue Miss and Advances Drug Development Programs | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - BioSpace
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals Reports Q2 Loss of $1.06 Per Share, Beati - GuruFocus
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - News-Times
(ENTA) Trading Report - news.stocktradersdaily.com
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - MSN
11 Best Breakout Stocks to Buy According to Analysts - Insider Monkey
JMP Securities maintains Enanta stock with $21 target - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
(ENTA) Investment Report - news.stocktradersdaily.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan
(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada
Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Enanta Pharmaceuticals Inc Azioni (ENTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
29,305 |
| Luu Brendan | Chief Business Officer |
Dec 06 '24 |
Sale |
8.06 |
2,283 |
18,401 |
36,047 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 06 '24 |
Sale |
8.06 |
866 |
6,980 |
17,918 |
| Or Yat Sun | Chief Scientific Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
369,109 |
| MELLETT PAUL J | Chief Fin. & Admin Officer |
Dec 06 '24 |
Sale |
8.06 |
2,591 |
20,883 |
91,710 |
| Luly Jay R. | President and CEO |
Dec 06 '24 |
Sale |
8.06 |
5,142 |
41,445 |
801,638 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 15 '24 |
Option Exercise |
8.99 |
5,375 |
48,321 |
27,092 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 15 '24 |
Sale |
17.08 |
5,375 |
91,805 |
21,717 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 11 '24 |
Sale |
15.07 |
4,299 |
64,786 |
23,988 |
| Rottinghaus Scott T. | Chief Medical Officer |
Jul 12 '24 |
Sale |
15.04 |
2,271 |
34,156 |
21,717 |
1.66%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):